FDA Okays Boehringer's Gilotrif, Qiagen EGFR Test, Providing New PGx Options for Advanced NSCLC | GenomeWeb

With the US regulatory approval for Boehringer Ingelheim's Gilotrif (afatinib), late-stage non-small cell lung cancer patients whose tumors are being driven by mutations that lead to the overexpression of the epidermal growth factor receptor now have two pharmacogenomic treatment options to battle their disease.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: genetic link between birth weight and adult-onset diseases, and more.

Even with all the current enthusiasm for gene therapies, Tech Review cautions that they are mostly in the early stages of development.

DNA phenotyping puts a potential face to a suspect in a nearly 25-year-old murder, the AP reports.

Researchers discuss the need for antibody standards at a meeting, NPR reports.